LONDON, England, April 14 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on April 12, 2026:

* * *

GSK presents positive data for B7-H4-targeted ADC in gynaecological cancers

* Mocertatug rezetecan achieved confirmed objective response rates of 62% in platinum-resistant ovarian cancer (PROC) and 67% in recurrent or advanced endometrial cancer (EC) in BEHOLD-1 study

* Current treatment options ar . . .

Click here for more information about our products